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Dr Anton Sidawy (Washington, DC). You presented three
ways to take care of infected grafts, how do you decide in your
practice which method to use? In situ rifampin-soaked grafts, in
situ femoropopliteal grafts, or whether you do an extra-anatomic
bypass? Is it the preference of the surgeon?
Dr Oderich. No, surgeon preference did not affect our man-
agement, which is evident by the use of in situ rifampin grafts in
nearly 90% of patients. We have a uniform approach at the Mayo
Clinic, and Dr Hallett, who is waiting to ask his question, can
perhaps comment on that later.
Aortic graft enteric erosions are different compared to primary
graft infections; type of organism, involvement of the graft, and
risk of reinfection is totally different. The vast majority of patients
with graft-enteric erosions are treated with a rifampin graft, except
for the minority (10%) who have a large abscess on preoperative
CT scan or excessive perigraft purulence on exploration. For those,
we use either a staged axillofemoral bypass or in situ femoropopli-primary graft infection and purulence, involvement of the groin, or
a virulent organism.
However, I would like to emphasize that the vast majority of
patients with graft enteric erosion, at least in our practice, have a
partial process that is localized to the main body or to a portion of
the graft limb, and oftentimes there are portions of the graft that
are well incorporated and can be preserved, which minimize the
operation.
Dr John Jeb Hallett (Charleston, SC). I rise to congratulate
you on following up on these challenging patients. Historical
credit should be given to Dr Denton Cooley and his surgeons who
really presented this idea back in the 1980s, and it was from their
ideas that we began to use the in situ techniques and rifampin at the
Mayo Clinic. At the time, in situ management of aortic graft
infections was heresy. Therefore, it is gratifying to hear your report
today of excellent and durable results.
I have one question: Is there something special about rifampin
that some other antibiotic does not offer?
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Indeed, the credit is to the Texas-Houston group and this is
acknowledged in the manuscript. Rifampin is one of the antibiotics
that has been studied and has excellent bonding to polyester grafts.
The intent initially was to prevent low-grade infections caused by
staph epidermidis and staph aureus. It does have excellent coverage
for some of the other gram-positive organisms such as streptococcus
viridans and intermediate coverage to some of the gram-negative
organisms. Recently, clinical use of rifampin grafts has been broad-
ened to other types of infections, but probably rifampin is not the
main factor that decreased reinfection rates in our study. I think it
is the whole package of the patient selection, the use of rifampin,
the omental wrapping, the debridement, and the use of postoper-
ative oral antibiotics that accounts for these outcomes. Omental
wrapping is a key factor and was demonstrated previously to reduce
reinfections.
Dr William Quinones-Baldrich (Los Angeles, Calif). In the
report of your prior experience with treatment of aortoenteric
erosion and fistulas, you had a recurrence rate of 3%. The recur-
rence rate reported today was 4%. You are performing a number of
other maneuvers that are intended to reduce the recurrence rate.
There is nothing wrong with soaking the graft in rifampin, but the
question remains: Does rifampin really make a difference?
Dr Oderich.Well, the only way to would be to do a prospec-
tive study, which is not possible with this disease.
Based on experimental studies and clinical experience, ri-
fampin does add by decreasing the chance of the graft of being
colonized or infected. That has been tested for other organisms or
in experimental studies, it has not been tested for other gram-
negative organisms or streptococcus. Therefore, we do not know the
definitive answer of that. We do continue to use this protocol, but
we believe that other factors such as patient selection, debride-
ment, omental wrapping, and IV and oral antibiotics are very
important for good results.
Dr K. Wayne Johnston (Toronto, Ontario, Canada). Differ-
ent manufacturers coat their grafts with different materials. Am Icorrect that rifampin binds most effectively to one graft type rather
than another?
Dr Oderich. The two grafts that were tested most were
collagen-impregnated or gelatin-impregnated grafts. Both bind
rifampin effectively on experimental studies. Some investigators
postulate that collagen grafts may denature the rifampin and
decrease the antibacterial activity.
The selection of the type of graft has not affected the outcome
in our study. This selection was based on surgeon preference in our
practice with a distribution of 70% gelatin and 30% collagen.
Dr Robert Rhee (Pittsburgh, Pa). These results are encour-
aging, and I was wondering if you have had any experience with
graft infections or aorto-esophageal fistulas involving the thoraco-
abdominal aorta? In other words, in situations in which you do not
really have a choice except to do an in-line reconstruction?
Dr Oderich. We have treated aortoesophageal fistulas after
thoracic stent grafts with a rifampin-soaked graft, but the experi-
ence is small to make recommendations. One factor is coverage of
the graft with omentum, which can be challenging albeit possible
in the chest.
Dr Richard Cambria (Boston, Mass). We have done about 30
of these. In addition, although we do not have the numbers or the
duration of follow-up, we do not know of a case of reinfection. In
addition, particularly the way that you selected your patients and
you pointed out that frequently the infection is localized, this
ought to work.
My question is: Have you used it in native infected aneurysms?
Because we have in selected cases as well.
DrOderich. Thank you for your comments, Dr Cambria. We
have used this in mycotic aneurysms. Actually, I recently did a case
of a perivisceral mycotic aneurysm using this technique. Moreover,
the reinfection rate for mycotic aneurysms was low at 4% in a
previous series that we published 10 years ago. Of course, patients
that have virulent organisms, such as MRSA, pseudomonas aerugi-
nosa are best suited for other types of reconstruction such as
femoral vein graft.
